Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRIV-03
- Development stage
- Preclinical
- Lead developer
- Genovyn
- Modality
- Small Molecules
01
Overview
TRIV-03 is a preclinical-stage multi-target small molecule combination therapy being developed by Genovyn, through its subsidiary Tripsovyn, for the treatment of triple-negative breast cancer (TNBC). It is designed to target multiple pathways independently of estrogen, progesterone, and HER2 receptors, offering a novel approach to treating aggressive and hard-to-treat breast cancers.
Beyond the preview
Go deeper on TRIV-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRIV-03.